RxDoctor Payments Data

Angel Stanley

Psychiatric/Mental Health · Syracuse, NYNPI 1821470725

Payments from drug & device makers

$1,543in general payments, 2019–2025

Across 58 payments — averaging $26.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Teva Pharmaceuticals USA, Inc.$380
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$313
  • AbbVie$240
  • Alkermes, Inc.$107
  • Sunovion Pharmaceuticals Inc.$92
  • Otsuka America Pharmaceutical, Inc.$92
  • plus $320 from 10 others

What the payments were for

  • Food & beverage$1,45394%
  • Education$896%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,543 in reported general payments places this provider in the 75th percentile of 2,385 psychiatric/mental health providers in New York.

See all psychiatric/mental health providers in New York

Medicare billing

Part B allowed, 2024
$25,316
Medicare patients
61
Services billed
254

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VraylarCariprazine Hcl15$22,211
Lurasidone Hcl21$6,619
TrintellixVortioxetine Hydrobromide11$6,435
Aripiprazole85$3,298
KlonopinClonazepam12$3,191
Chlorpromazine Hcl28$2,272
Alprazolam180$2,056
Quetiapine Fumarate171$2,048
Clonazepam203$1,903
Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine62$1,823
Bupropion XlBupropion Hcl109$1,786
Escitalopram Oxalate62$1,558
Trazodone Hcl158$1,404
Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine30$1,354
Olanzapine59$1,259

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieVraylar$240$22,21115 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$14$6,43511 claims
Almatica Pharma LLCSertraline Hcl$14$482100 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 2,385 psychiatric/mental health providers in New York.

Other psychiatric/mental health in Syracuse

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →